Targeting mitochondria as a therapeutic anti-gastric cancer approach

Peticha Tanprasert1, Sirikan Limpakan Yamada1, Siriporn C Chattipakorn2,3

  • 1Division of Gastrointestinal Surgery and Endoscopy, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.

Insights

Mitochondria are crucial for gastric cancer cell survival and death. Targeting mitochondrial dynamics offers a promising new avenue for treating gastric cancer, improving outcomes beyond current chemotherapy.

Area of Science:

  • Oncology
  • Cell Biology
  • Mitochondrial Biology

Background:

  • Gastric cancer is a leading cause of cancer death worldwide.
  • Current chemotherapy for advanced gastric cancer has limited efficacy.
  • Mitochondria are vital for cell survival, apoptosis, and cancer development.

Purpose of the Study:

  • To review the role of mitochondrial homeostasis in gastric cancer.
  • To explore targeting mitochondrial dynamics as a therapeutic strategy for gastric cancer.

Main Methods:

  • Comprehensive literature review on mitochondrial function in gastric cancer.
  • Analysis of studies on mitochondrial dynamics (fission, fusion, mitophagy) in carcinogenesis.
  • Discussion of potential therapeutic interventions targeting mitochondria.

Main Results:

  • Mitochondria significantly influence gastric cancer cell fate and progression.
  • Mitochondrial dynamics, including fission, fusion, and mitophagy, are implicated in cancer development.
  • Targeting these dynamics presents a novel therapeutic approach.

Conclusions:

  • Understanding mitochondrial homeostasis is key to developing new gastric cancer treatments.
  • Targeting mitochondrial dynamics holds significant potential for overcoming chemotherapy resistance and improving patient outcomes.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K